1-3 of 3
Irit Avivi
Close
Sort by
Journal Articles

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

Clinical Trials & Observations
Armin Ghobadi, Javier Munoz, Jason R. Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole
Journal: Blood Advances
Blood Adv (2024) 8 (11): 2982–2990.
https://doi.org/10.1182/bloodadvances.2023011532
Published: 2024
Includes: Supplemental data
Journal Articles

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma

Shlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, Vladimir Vainstein, Miri Assayag, Tatyana Dubnikov Sharon, Sigal Grisariu, Batia Avni, Shlomo Elias, Rivka Alexander-Shani, Nomi Bessig, Alaa Shehadeh, Aseel Ishtay, Veronica Zelmanovich, Eran Zimran, Marjorie Pick, Ilan Roziner, Ron S. Kenett, Yael C. Cohen, Irit Avivi, Cyrille J. Cohen, Moshe E. E Gatt, Polina Stepensky
Journal: Blood Advances
Blood Adv bloodadvances.2024012967.
https://doi.org/10.1182/bloodadvances.2024012967
Published: 2024
Includes: Supplemental data
Journal Articles

Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Yair Herishanu, Irit Avivi, Shai Levi, Gabi Shefer, Yotam Bronstein, Miguel Morales Moshiashvili, Tomer Ziv, Lydia Scarfò, Chava Perry, Paolo Ghia
Journal: Blood Advances
Blood Adv (2022) 6 (1): 148–151.
https://doi.org/10.1182/bloodadvances.2021005998
Published: 2022
Includes: Supplemental data